Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alterity Therapeutics (ATHE) Change in Receivables (2016 - 2020)

Alterity Therapeutics has reported Change in Receivables over the past 4 years, most recently at $1.7 million for Q4 2018.

  • For Q4 2018, Change in Receivables rose 243.82% year-over-year to $1.7 million; the TTM value through Dec 2018 reached $1.8 million, up 326.34%, while the annual FY2025 figure was $67449.5, 97.78% down from the prior year.
  • Change in Receivables for Q4 2018 was $1.7 million at Alterity Therapeutics, up from -$884.5 in the prior quarter.
  • Over five years, Change in Receivables peaked at $1.7 million in Q4 2018 and troughed at -$2.2 million in Q4 2016.
  • A 4-year average of -$147161.0 and a median of -$884.5 in 2018 define the central range for Change in Receivables.
  • On a YoY basis, Change in Receivables climbed as much as 243.82% in 2018 and fell as far as 100.07% in 2018.
  • Year by year, Change in Receivables stood at -$2.0 million in 2015, then fell by 12.35% to -$2.2 million in 2016, then surged by 44.88% to -$1.2 million in 2017, then surged by 243.82% to $1.7 million in 2018.
  • Business Quant data shows Change in Receivables for ATHE at $1.7 million in Q4 2018, -$884.5 in Q2 2018, and -$1.2 million in Q4 2017.